Immunocore
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The compa...
Latest News
8 days ago · globenewswire.com
Immunocore to present at upcoming investor conferences(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
11 days ago · globenewswire.com
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaIn 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
11 days ago · globenewswire.com
Immunocore reports third quarter financial results and provides a business updateKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
19 days ago · globenewswire.com
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
1 month ago · globenewswire.com
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes Preclinical data supporting unique mechanism of action recently published in Science Advances (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that the first patient with type 1 diabetes (T1D) has been dosed in the Phase 1 trial (NCT07493122) of IMC-S118AI1. IMC-S118AI, the Company's first candidate for autoimmune diseases, is a novel bispecific molecule designed to down-modulate the immune system in a tissue-specific manner to protect beta cells under T cell attack in T1D.
2 months ago · zacks.com
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyIMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
2 months ago · seekingalpha.com
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptImmunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · globenewswire.com
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297). TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator's Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy.
3 months ago · zacks.com
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
3 months ago · zacks.com
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More MomentumImmunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IMCR